The Effects of Anesthetics on Brain Network Connectivity in Patients With Supratentorial Glioma

Capital Medical University

Status: Enrolling

Conditions: Propofol; Dexmedetomidine; Brain Network Connectivity; Postoperative Delirium

Treatments: Drug: Dexmedetomidine; Drug: Remimazolam Injection; Drug: Propofol

Study type: Observational

Funder types: Other

Identifiers

NCT06138340

20230808

Details and patient eligibility

About

Perioperative anesthesia can affect postoperative cognitive function. In our previous study, intraoperative dexmedetomidine (Dex) infusion reduced the incidence of delirium within the first 5 days after brain tumor. However, the mechanism is still unclear. With the development of neuroimaging, multimodal neuroimaging technology provide a new method to explore the underlying mechanism. Therefore, the purpose of this study is to analyze the alterations of brain network under sedation and anesthesia by different anesthetics in patients with supratentorial glioma and their association with cognition.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed as unilateral supratentorial glioma by MRI
• Selective operation
• Age over 18 years old
• ASA I-II
• Right handedness

Exclusion criteria

• History of cerebrovascular disease, brain trauma, chemotherapy and radiotherapy, or psychotropic drugs
• History of intracranial surgery
• Drug and/or alcohol abuse
• History of dementia or mental illness
• Pregnant or lactating women
• Contraindications for MRI
• Severe bradycardia (heart rate less than 40 beats per minute), sick sinus syndrome or second-to-third degree atrioventricular block
• Severe hepatic or renal dysfunction

Trial design

120 participants in 3 patient groups

Dex group

Description:

Participants will be sedated and maintained by dexmedetomidine.

Treatment:

Drug: Dexmedetomidine

Propofol group

Description:

Participants will be sedated and maintained by propofol.

Treatment:

Drug: Propofol

Remimazolam group

Description:

Participants will be sedated and maintained by remimazolam.

Treatment:

Drug: Remimazolam Injection